323 related articles for article (PubMed ID: 7837724)
1. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
Tomioka H; Saito H
Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
[TBL] [Abstract][Full Text] [Related]
2. [Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections].
Kawahara S; Nagare H
Kekkaku; 1998 Feb; 73(2):77-82. PubMed ID: 9545700
[TBL] [Abstract][Full Text] [Related]
3. [Effects of half-sized secretory leukocyte protease inhibitor and Chinese traditional medicines, yokuinin and mao-bushi-saishin-to, on therapeutic efficacies of benzoxazinorifamycin KRM-1648 against Mycobacterium avium complex infection induced in mice].
Sato K; Shimizu T; Tomioka H; Kawahara S
Kekkaku; 1998 Aug; 73(8):501-6. PubMed ID: 9780605
[TBL] [Abstract][Full Text] [Related]
4. [In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Apr; 68(4):293-9. PubMed ID: 8497119
[TBL] [Abstract][Full Text] [Related]
5. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice].
Akaki T; Sato K; Shimizu T; Tomioka H; Kawahara S
Kekkaku; 1997 Aug; 72(8):491-7. PubMed ID: 9293712
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
Sato K; Tomioka H
Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic effects of benzoxazinorifamycin KRM-1648 administered alone or in combination with glycyrrhizin against Mycobacterium avium complex infection in mice].
Shimizu T; Tomioka H; Sato K; Akaki T; Ogasawara K; Kawahara S
Kekkaku; 1999 Aug; 74(8):617-21. PubMed ID: 10487030
[TBL] [Abstract][Full Text] [Related]
9. [In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis].
Sato K; Tomioka H; Saito H; Kawahara S; Hidaka T
Kekkaku; 1996 Aug; 71(8):459-64. PubMed ID: 8831191
[TBL] [Abstract][Full Text] [Related]
10. [Expectation of new antituberculous drugs and targeting therapy for treatment of mycobacterial infections].
Tomioka H
Kekkaku; 1993 Nov; 68(11):723-30. PubMed ID: 8264129
[TBL] [Abstract][Full Text] [Related]
11. [New drugs against tuberculosis and nontuberculous mycobacterial infections: a review].
Amitani R; Kuze F
Kekkaku; 1994 Nov; 69(11):711-7. PubMed ID: 7837725
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, in Mycobacterium intracellulare infection induced in mice].
Saito H; Tomioka H; Sato K; Hidaka T
Kekkaku; 1994 Feb; 69(2):59-63. PubMed ID: 8126989
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, administered at the different periods of infection in Mycobacterium intracellulare--infected mice].
Tomioka H; Sato K; Saito H; Hidaka T
Kekkaku; 1993 Oct; 68(10):631-5. PubMed ID: 8255070
[TBL] [Abstract][Full Text] [Related]
14. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
Sato K; Ogasawara K; Akaki T; Tomioka H
Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
[TBL] [Abstract][Full Text] [Related]
15. [Chemoprophylaxis against Mycobacterium avium complex infection induced in mice].
Saito H; Murakami K; Kobayashi K; Gidoh M; Hidaka T; Kwon HH
Kekkaku; 1999 Sep; 74(9):677-81. PubMed ID: 10535281
[TBL] [Abstract][Full Text] [Related]
16. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
Tomioka H
Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model].
Doi N
Kekkaku; 1998 Feb; 73(2):53-64. PubMed ID: 9545697
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.
Saito H; Tomioka H; Sato K; Kawahara S; Hidaka T; Dekio S
Tuber Lung Dis; 1995 Feb; 76(1):51-8. PubMed ID: 7718848
[TBL] [Abstract][Full Text] [Related]
19. [Mechanism of bacterial regrowth at the sites of infection in Mycobacterium avium complex-infected mice during treatment with chemotherapeutic agents].
Sato K; Tomioka H; Maw WW; Saito H
Kekkaku; 1995 Dec; 70(12):673-8. PubMed ID: 8551714
[TBL] [Abstract][Full Text] [Related]
20. [Current status and perspectives on the development of rifamycin derivative antibiotics].
Hidaka T
Kekkaku; 1999 Jan; 74(1):53-61. PubMed ID: 10067056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
